SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Pascual Salcedo Dora)
 

Sökning: WFRF:(Pascual Salcedo Dora) > BAFF predicts immun...

  • Hernández-Breijo, BorjaImmuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, Madrid, Spain (författare)

BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors

  • Artikel/kapitelEngelska2021

Förlag, utgivningsår, omfång ...

  • 2021-06-02
  • Springer Nature,2021
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:oru-92145
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-92145URI
  • https://doi.org/10.1038/s41598-021-91177-4DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:147346889URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Funding Agency:Nordic Pharma
  • Immunogenicity related to treatment with TNF inhibitors (TNFi) is one of the causes for the decreased attainment of clinical response in patients with rheumatoid arthritis (RA). The B-cell activating factor (BAFF) may be playing a role in the development of immunogenicity. The objective of this study was to analyse the association of baseline concentration of serum B-cell activating factor (BAFF) with immunogenicity after 6 months of TNFi treatment. A total of 127 patients with RA starting a TNFi (infliximab, adalimumab, certolizumab pegol or golimumab) were followed-up for 6 months. Serum samples were obtained at baseline and at 6 months and anti-drug antibody (ADA) and BAFF concentrations were measured. Logistic regression models were employed in order to analyse the association between BAFF concentrations and immunogenicity. Receiver operating characteristic analysis was performed to determine the BAFF concentrations with a greater likelihood of showing immunogenicity association. At 6 months, 31 patients (24%) developed ADA. A significant interaction between the age and baseline BAFF concentration was found for the development of ADA (Wald chi-square value = 5.30; p = 0.02); therefore, subsequent results were stratified according to mean age (≤ / > 55 years). Baseline serum BAFF concentration was independently associated with ADA development only in patients over 55 years (OR = 1.51; 95% CI 1.03-2.21). Baseline serum BAFF ≥ 1034 pg/mL predicted the presence of ADA at 6 months (AUC = 0.81; 95% confidence interval (CI) 0.69-0.93; p = 0.001; positive likelihood ratio = 3.7). In conclusion, our results suggest that the association of BAFF concentration and immunogenicity depends on the patient's age. Baseline serum BAFF concentration predicts the presence of ADA within 6 months of TNFi therapy in older patients with RA.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Navarro-Compán, VictoriaImmuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, Madrid, Spain; Department of Rheumatology, La Paz University Hospital, Madrid, Spain (författare)
  • Plasencia-Rodríguez, ChamaidaImmuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, Madrid, Spain; Department of Rheumatology, La Paz University Hospital, Madrid, Spain (författare)
  • Parodis, Ioannis,1981-Karolinska Institutet,Örebro universitet,Institutionen för medicinska vetenskaper,Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Department of Gastroenterology, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden(Swepub:oru)isps (författare)
  • Gehin, Johanna E.Department of Medical Biochemistry, Oslo University Hospital, Radiumhospitalet, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway (författare)
  • Martínez-Feito, AnaImmuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, Madrid, Spain; Immunology Unit, La Paz University Hospital, Madrid, Spainn (författare)
  • Novella-Navarro, MartaImmuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, Madrid, Spain; Department of Rheumatology, La Paz University Hospital, Madrid, Spain (författare)
  • Mezcua, AraceliImmunology Unit, La Paz University Hospital, Madrid, Spain (författare)
  • Warren, David J.Department of Medical Biochemistry, Oslo University Hospital, Radiumhospitalet, Oslo, Norway (författare)
  • Nozal, PilarImmunology Unit, La Paz University Hospital, Madrid, Spain; Center for Biomedical Network Research on Rare Diseases (CIBERER U754), Madrid, Spain (författare)
  • Pascual-Salcedo, DoraImmuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, Madrid, Spain (författare)
  • Balsa, AlejandroImmuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, Madrid, Spain; Department of Rheumatology, La Paz University Hospital, Madrid, Spain (författare)
  • Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, Madrid, SpainImmuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, Madrid, Spain; Department of Rheumatology, La Paz University Hospital, Madrid, Spain (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Scientific Reports: Springer Nature11:12045-2322

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy